The antibody positivity (aka antibody reactive) rate measures the proportion of people tested who produce a reactive antibody test. The numerator and denominator capture anyone who has ever been exposed to HCV, including those who have cleared it on their own or through treatment. An upward trend in this curve is desirable because it lets us know how well we're doing in testing those who are highly impacted by HCV. For example, a low positivity rate might let us know we're not reaching and testing the right people, therefore we should shift our strategies, location of services, etc. 

Updated December 2021

Description of data: The percent of positive antibody tests among all HCV antibody tests given at SFDPH-funded CBOs per quarter. 

*Data is considered preliminary until 3 months after the end of the quarter's closing.

Time:

• Data time frame: 2019-current
• Data as of May 25, 2022

Inclusion/Exclusion Criteria: 11 SFDPH-funded CBOs

Description of Data Source: CBOs complete an SFDPH HCV data testing form for every client that receives testing services. CBOs can complete the form via paper or submit electronically. 

Reference for QI Plan: 

Relevant PTL Strategic Priorities:

• SP1 - increase mobile testing
• SP2 - increase venue-based testing
• SP4 - support rapid HCV start initiatives for PWID
• SP7 - improve awareness of HCV among the public
• SP8 - reduce HCV-related stigma via social marketing campaign
• SP9 - improve community leadership
• SP11 - engage and empower community members